



RECEIVED

MAR 11 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

APPLICANT: Gao *et al.*) ATTORNEY DOCKET NO.: C-34071-US
S)
SERIAL NO.: 10/047,222) GROUP ART UNIT: 1614
)
FILED: January 15, 2002) EXAMINER: Unknown
TITLE: PHARMACEUTICAL COMPOSITION HAVING REDUCED TENDENCY
FOR DRUG CRYSTALLIZATION
DATE: March 6, 2003

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement is being deposited with the United States Postal Service as First Class Mail in one package(s) addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 6, 2003.

Bernadette Y. Harper
Bernadette Y. Harper

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97(b)

Applicants hereby submit copies of patents, publications and/or other information of which they are aware and which may be related to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56 and §§ 1.97-1.98, as supplemented by MPEP §609. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application. No fee is believed payable; however, if it is determined that a fee is payable, please charge Deposit Account No. 19-1025.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR § 1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.

Respectfully submitted,



David B. Fournier
Agent for Applicant
Registration No. 51,696
Tel. 847-581-5144

Address correspondence to:

Pharmacia Corporation
P.O. Box 1027
St. Louis, MO 63006

Enclosures:

Form PTO-1449
Copies of cited documents
International Search Report – PCT/US02/00971
Post Card